PeptidePeptideErythropoiesis-stimulating agentGlycoprotein hormone

Darbepoetin Alfa

Also known as Aranesp · NESP · Novel erythropoiesis-stimulating protein

Written by enwyReviewed 5 Aug 20262 sources0 comments

Darbepoetin alfa is a hyperglycosylated, longer-acting analogue of erythropoietin with two extra N-linked carbohydrate chains, extending its half-life so it can be dosed less frequently. Licensed for anaemia, it has been detected in high-profile doping cases (notably at the 2002 Winter Olympics). Prohibited by WADA at all times.

01 Overview

Engineered with five N-linked glycosylation sites (versus three in native EPO), darbepoetin has a roughly threefold longer terminal half-life, allowing weekly or fortnightly dosing for renal and cancer anaemia. Its mechanism is identical to EPO: stimulation of the EPO receptor and expansion of red cell mass.\n\nIts longer action and distinct glycosylation initially made it attractive to dopers, but it is readily distinguished from endogenous EPO on isoelectric focusing and was central to positive tests among cross-country skiers in 2002. The cardiovascular risks mirror EPO: thrombosis, hypertension and, in oncology trials, signals of increased mortality and tumour progression at high haemoglobin targets.

02 Mechanism

Binds and activates the erythropoietin receptor exactly as native EPO, but its additional sialic-acid-rich carbohydrate chains slow clearance, giving a longer duration of erythropoietic stimulation per dose.

03 Dosing

Tier	Dose	Route	Notes
Renal anaemia (medical)	0.45–0.75 mcg/kg/wk	SubQ	Or every 2 weeks; titrated to haemoglobin
Doping (illicit)	10–40 mcg	SubQ	Reported illicit fixed doses; not a recommendation

04 Effects

Effect	Magnitude	Evidence
Sustained rise in red cell massLonger-acting erythropoiesis raises haemoglobin with less frequent injections than EPO.	Hb +1-2 g/dL	Clinical
Improved aerobic performanceBy expanding oxygen-carrying capacity it improves endurance similarly to conventional EPO.	Comparable to EPO	Observational

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
ThromboembolismAs with EPO, raised haematocrit predisposes to stroke, MI and venous thromboembolism.	Life-threatening	Dose-dependent	Clinical
HypertensionBlood pressure elevation similar to EPO.	Moderate	Common	Clinical

06 Legal status

United States

Prescription biologic (FDA)

WADA-prohibited in sport · as of Jan 2026

07 References

Detection of darbepoetin alfa (NESP) in doping controlNature / anti-doping literature, 2002

WADA Prohibited List — S2World Anti-Doping Agency

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.